Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

Compare

11,736 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMY Analyst Ratings

Hold

5 Buy

14 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Bristol-Myers

Squibb

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

$50.93

▲(14.35% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $50.93 with a high forecast of $65.00 and a low forecast of $34.00. The average price target represents a 14.35% change from the last price of $44.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","66":"$66","41.25":"$41.3","49.5":"$49.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,41.25,49.5,57.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.79,48.19076923076923,49.59153846153846,50.99230769230769,52.39307692307692,53.793846153846154,55.19461538461538,56.59538461538462,57.996153846153845,59.39692307692307,60.79769230769231,62.19846153846154,63.59923076923077,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.79,47.10846153846154,47.426923076923075,47.745384615384616,48.06384615384615,48.38230769230769,48.70076923076923,49.01923076923077,49.33769230769231,49.65615384615385,49.97461538461538,50.293076923076924,50.61153846153846,{"y":50.93,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.79,45.80615384615385,44.82230769230769,43.83846153846154,42.854615384615386,41.87076923076923,40.886923076923075,39.903076923076924,38.919230769230765,37.93538461538461,36.95153846153846,35.9676923076923,34.98384615384615,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.84,"date":1727740800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":51.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.78,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.42,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$65.00

Average Price Target$50.93

Lowest Price Target$34.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

$64

Buy

43.69%

Upside

Reiterated

10/08/25

Piper Sandler Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)We reiterate our Overweight rating.

Evan Seigerman

BMO Capital

$47

Hold

5.52%

Upside

Reiterated

10/03/25

Hold Rating Issued for Bristol-Myers Squibb Amid Declining Cobenfy Prescriptions and Revenue Forecast Miss

Unknown Analyst

CFRA

Not Ranked

CFRA

$55

Buy

23.48%

Upside

Upgraded

10/01/25

Positive Report for Bristol-Myers Squibb (BMY) from CFRACFRA upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Hold to Buy with a price target of $55.00.

Terence Flynn

Morgan Stanley

$34

Sell

-23.66%

Downside

Reiterated

09/30/25

Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (NYSE: BMY), Boston Scientific (NYSE: BSX) and Zenas BioPharma, Inc. (NASDAQ: ZBIO)

Courtney Breen

Bernstein

―

Hold

―

Reiterated

09/30/25

Bernstein Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)We rate LLY, GILD, AMGN Outperform & PFE, BMY, MRK, ABBV, MRNA as Market-Perform.

David Risinger

Leerink Partners

―

Buy

―

Reiterated

09/26/25

Geoff Meacham

Citi

$47

Hold

5.52%

Upside

Reiterated

09/24/25

Citi Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

Matt Phipps

William Blair

―

Hold

―

Reiterated

09/23/25

Hold Rating Maintained for Bristol-Myers Squibb Amid Uncertainty in CELMoD Franchise DevelopmentsWe believe the most strategically important results for the CELMoDs will come from head-to-head trials against Revlimid and Pomalyst (EXCALIBER- GOLSEEK-4), given these would be key in supporting franchise transition of the IMiD drugs, with Revlimid and Pomalyst continuing to face significant generic erosion. We continue to view the CELMoD franchise as among the company’s most important Phase III programs, which along with success of other late-stage assets such as milvexian and the continued launch momentum for Cobenfy could strengthen the company’s longer-term outlook.

Chris Schott

J.P. Morgan

$65

Buy

45.94%

Upside

Reiterated

09/16/25

Bristol-Myers Squibb (BMY) Gets a Buy from J.P. MorganWe are establishing a Dec 2026 price target of $65 (vs prior Dec 2025 PT of $65)

Veda Pharmyne

TR | OpenAI - 4o

$47→$53

Buy

18.99%

Upside

Upgraded

08/14/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

$55→$45

Hold

1.03%

Upside

Reiterated

08/13/25

Cantor Fitzgerald Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)Cantor Fitzgerald analyst Carter Gould lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $45.00 (from $55.00) while maintaining a Neutral rating.

Narumi Nakagiri

Daiwa

$42

Hold

-5.70%

Downside

Downgraded

08/05/25

Bristol Myers downgraded to Neutral from Outperform at DaiwaBristol Myers downgraded to Neutral from Outperform at Daiwa

Trung Huynh

UBS

$52→$46

Hold

3.28%

Upside

Reiterated

08/01/25

Bristol Myers price target lowered to $46 from $52 at UBSBristol Myers price target lowered to $46 from $52 at UBS

Tim Anderson

Bank of America Securities

$56→$50

Hold

12.26%

Upside

Reiterated

08/01/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

08/01/25

Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

$64

Buy

43.69%

Upside

Reiterated

10/08/25

Piper Sandler Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)We reiterate our Overweight rating.

Evan Seigerman

BMO Capital

$47

Hold

5.52%

Upside

Reiterated

10/03/25

Hold Rating Issued for Bristol-Myers Squibb Amid Declining Cobenfy Prescriptions and Revenue Forecast Miss

Unknown Analyst

CFRA

Not Ranked

CFRA

$55

Buy

23.48%

Upside

Upgraded

10/01/25

Positive Report for Bristol-Myers Squibb (BMY) from CFRACFRA upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Hold to Buy with a price target of $55.00.

Terence Flynn

Morgan Stanley

$34

Sell

-23.66%

Downside

Reiterated

09/30/25

Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (NYSE: BMY), Boston Scientific (NYSE: BSX) and Zenas BioPharma, Inc. (NASDAQ: ZBIO)

Courtney Breen

Bernstein

―

Hold

―

Reiterated

09/30/25

Bernstein Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)We rate LLY, GILD, AMGN Outperform & PFE, BMY, MRK, ABBV, MRNA as Market-Perform.

David Risinger

Leerink Partners

―

Buy

―

Reiterated

09/26/25

Geoff Meacham

Citi

$47

Hold

5.52%

Upside

Reiterated

09/24/25

Citi Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

Matt Phipps

William Blair

―

Hold

―

Reiterated

09/23/25

Chris Schott

J.P. Morgan

$65

Buy

45.94%

Upside

Reiterated

09/16/25

Bristol-Myers Squibb (BMY) Gets a Buy from J.P. MorganWe are establishing a Dec 2026 price target of $65 (vs prior Dec 2025 PT of $65)

Veda Pharmyne

TR | OpenAI - 4o

$47→$53

Buy

18.99%

Upside

Upgraded

08/14/25

AI Generated ArticleAI Generated Article

Carter Gould

Cantor Fitzgerald

$55→$45

Hold

1.03%

Upside

Reiterated

08/13/25

Narumi Nakagiri

Daiwa

$42

Hold

-5.70%

Downside

Downgraded

08/05/25

Bristol Myers downgraded to Neutral from Outperform at DaiwaBristol Myers downgraded to Neutral from Outperform at Daiwa

Trung Huynh

UBS

$52→$46

Hold

3.28%

Upside

Reiterated

08/01/25

Bristol Myers price target lowered to $46 from $52 at UBSBristol Myers price target lowered to $46 from $52 at UBS

Tim Anderson

Bank of America Securities

$56→$50

Hold

12.26%

Upside

Reiterated

08/01/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

08/01/25

Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

1 Month

xxx

Success Rate

9/19 ratings generated profit

Average Return

-1.82%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.37% of your transactions generating a profit, with an average return of -1.82% per trade.

3 Months

xxx

Success Rate

15/25 ratings generated profit

Average Return

+2.38%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.38% per trade.

1 Year

Terence FlynnMorgan Stanley

Success Rate

20/25 ratings generated profit

Average Return

+9.31%

reiterated a sell rating 11 days ago

Copying Terence Flynn's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +9.31% per trade.

2 Years

xxx

Success Rate

21/25 ratings generated profit

Average Return

+13.94%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.00% of your transactions generating a profit, with an average return of +13.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMY has received 9 Buy Ratings, 19 Hold Ratings, and 1 Sell Ratings. BMY average Analyst price target in the past 3 months is 50.93.

Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is $1.62 with a range of $1.43 to $1.81. The previous quarter’s EPS was $1.46. BMY beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year BMY has Preformed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is $11.80B with a range of $11.62B to $12.06B. The previous quarter’s sales results were $12.27B. BMY beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year BMY has Preformed in-line its overall industry.

BMY Stock Forecast FAQ

What is BMY’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb Company’s 12-month average price target is 50.93.

What is BMY’s upside potential, based on the analysts’ average price target?

Bristol-Myers Squibb Company has 14.35% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMY a Buy, Sell or Hold?

Bristol-Myers Squibb Company has a consensus rating of Hold which is based on 5 buy ratings, 14 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb Company’s price target?

The average price target for Bristol-Myers Squibb Company is 50.93. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $34.00. The average price target represents 14.35% Increase from the current price of $44.54.

What do analysts say about Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of BMY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

BMY Analyst Ratings

BMY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol-Myers Squibb

BMY Analyst Recommendation Trends

BMY Financial Forecast

BMY Earnings Forecast

BMY Sales Forecast

BMY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts